相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
Martin Tolar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Martin Tolar et al.
ALZHEIMERS & DEMENTIA (2020)
Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways
Steven M. Greenberg et al.
NATURE REVIEWS NEUROLOGY (2020)
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks
Heather Guthrie et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies
Sara Linse et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
Yannick Chantran et al.
FRONTIERS IN IMMUNOLOGY (2019)
ABBY A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
Jeffrey L. Cummings et al.
NEUROLOGY (2018)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Joseph W. Arndt et al.
SCIENTIFIC REPORTS (2018)
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
Susanne Ostrowitzki et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis
Kirsten L. Viola et al.
ACTA NEUROPATHOLOGICA (2015)
The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-beta Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice
Stina Tucker et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease
Lars Lannfelt et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies
Fabrizio Piazza et al.
ANNALS OF NEUROLOGY (2013)
Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
Kristina Magnusson et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
Luke A. Miles et al.
SCIENTIFIC REPORTS (2013)
Isolated Amyloid-β(1-42) Protofibrils, But Not Isolated Fibrils, Are Robust Stimulators of Microglia
Geeta S. Paranjape et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
Ronald B. DeMattos et al.
NEURON (2012)
Large Aggregates Are the Major Soluble Ab Species in AD Brain Fractionated with Density Gradient Ultracentrifugation
Dag Sehlin et al.
PLOS ONE (2012)
Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
Brian O'Nuallain et al.
JOURNAL OF NEUROSCIENCE (2010)
Consequence of A immunization on the vasculature of human Alzheimers disease brain
D. Boche et al.
BRAIN (2008)
Physiochemical characterization of the Alzheimer's disease-related peptides Aβ1-42Arctic and Aβ1-42wt
Ann-Sofi Johansson et al.
FEBS JOURNAL (2006)
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor proteintransgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β
MM Racke et al.
JOURNAL OF NEUROSCIENCE (2005)
Amyloid β peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology
J Attems et al.
ACTA NEUROPATHOLOGICA (2004)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
C Nilsberth et al.
NATURE NEUROSCIENCE (2001)
分享论文
